Placenta and endometrium carry out steroidogenic biotransformation reactions such as 6-ft-hydroxylation of cortisol, a reaction characteristic of the dominant family of cytochromes P450 in human liver, CYP3A. To investigate the possible role in these extrahepatic tissues of the CYP3A microsomal hemoproteins, we analyzed placental and endometrial microsomes on Western blots developed with an anti-human CYP3A antibody. We found an immunoreactive 51,500 D protein that migrated between CYP3A3 (HLp) and CYP3A5 (HLp2) identical with CYP3A7 (HFLa). CYP3A7, a form found prominently in human fetal liver microsomes, was first isolated as a liver 16-adehydroepiandrosterone-sulfate hydroxylase. Northern blot analysis of total RNA isolated from placenta or from endometrium demonstrated a single band that cross-hybridized with a CYP3A7 cDNA. Amplification of the same RNA samples with the use of primers specific for CYP3A7, produced a 552-bp segment that had the predicted size and the same DNA sequence as does liver CYP3A7 cDNA. Hybridizable endometrial CYP3A7 mRNA was detected more frequently (six of seven samples) and in higher amounts (-12-fold higher) in pregnant compared with nonpregnant women (4 of 12 samples). In addition, during the secretory phase of the menstrual cycle CYP3A7 expression was sixfold higher than in the one sample from the proliferative phase that had detectable CYP3A7 mRNA. Moreover, the amounts of placental and endometrial CYP3A7 mRNA and protein increased substantially from the first to the second trimester of pregnancy. We conclude that placenta and endometrium express the same P450 as is found in fetal liver. These tissues represent a previously unrecognized and quantitatively important site for 6-ft-hydroxylation and 16-a-hydroxylation of specific steroid precursors, possibly for protection of the fetus from the toxic effects of endogenous steroids and foreign substrates. (J. Clin. Invest. 1993. 
Introduction
The cytochromes P450 are a multigene family of microsomal hemoproteins, most abundant in the liver, that play a critical role in the biooxidation ofsuch xenobiotics as drugs, pesticides, and carcinogens (1) (2) (3) (4) as well as endogenous agents including fatty acids, inflammatory mediators, and steroid hormones (5, 6) . Although it has been amply documented that several forms of P450 in liver microsomes catalyze the stereospecific hydroxylation of cortisol, testosterone, androstendione, and progesterone (7-1 1), the physiological importance, if any, of these reactions in the liver in vivo other than as possible accessory disposal pathways is unclear ( 12) . However, the development of sensitive techniques for measuring P450 proteins and mRNAs has led to the recognition that virtually all tissues contain one or more forms of P450 (6) and that these extrahepatic P450s are likely to participate in tissue specific-biotransformations.
For example, the placenta is not merely a protective barrier for the fetus but also facilitates maternal-to-fetal transfer of nutritional, metabolic, and hormonal agents and actively synthesizes steroid hormones, particularly estrogens ( 13) . It is believed that estrogen biosynthesis in the placenta uses dehydroepiandrosterone-sulfate (DHEA-s),' a precursor produced in large amounts by the fetal adrenals. In high concentrations, DHEA-s inhibits cell proliferation ( 14) , interferes with cellular respiration ( 15) , promotes cervical ripening ( 16) , and inhibits placental progesterone biosynthesis ( 17) . These events may adversely affect fetal survival. In contrast, the 16-a-hydroxylated form of DHEA-s does not inhibit progesterone biosynthesis ( 17) and may be less toxic to the fetus. Recently, a form of cytochrome P450 termed HFLa (CYP3A7) that has been thought to be expressed in fetal liver exclusively (18) (19) (20) (21) (22) (23) (24) (25) was found to catalyze 16-a-hydroxylation of DHEA-s (23) . One interpretation of this finding might be that 16-a-hydroxylation of DHEA-s serves a self protective fetal function confined to the developing liver.
There are some clues, however, that placental tissues could contain cytochromes P450 of the 3A family. Placental tissues readily oxidize cortisol to 6-,B-hydroxycortisol, an activity associated with cytochromes of the 3A family (7, 9) . Such a function might explain the high levels of 6-f3-hydroxycortisol in the amniotic fluid (26, 27) . Even though placental tissues gave no evidence for 16-a-hydroxylation of DHEA-s in early studies ( 12) , a recent study found that placental cultures can, in the absence ofexogenous steroid precursors, synthesize both the 16 a-hydroxylated form of DHEA-s and estriol (28) . Because 
Procedures
Microsomes and immunoblot analysis. Microsomes were prepared and stored as previously described ( 18, 30, 31 ) . Protein concentration was determined colorimetrically as previously described ( 18, 30, 31 (33) . Positive phage were rescreened by use of this probe. Strongly positive clones were purified by multiple screening of isolated plaques at high stringency (0.1X SSC and 0.2% SDS, 520C). A single positive clone, which contained a single internal EcoRI restriction site and a 1,566-bp insert (bp 404-1,970 of CYP3A7 [24] ), was subcloned into either pGEM 3Z or M 13 mpl 8 or 19 and sequenced as described below.
Northern blot. Total RNA was isolated from specimens by guanidinium thiocyanate-phenol-chloroform extraction (34) . The RNA (30 Mug) was fractionated by electrophoresis in a formaldehyde denaturing agarose gel (34) and transferred to nitrocellulose by capillary diffusion and then baked at 80'C under vacuum for 2 h. Prehybridization and hybridization with the 32P-radiolabeled CYP3A7 cDNA were as described previously (35) . The size of the CYP3A7 hybridizing mRNA band was estimated by linear interpolation of 28S (4.9-kb) and 18S ( 1.95-kb) RNA standards. The samples of placenta and endometrium used in these studies were not cross-contaminated as judged by the absence of specific markers, placental lactogen mRNA and endometrial interleukin-1 B hybridizable mRNA, respectively (34) . Northern blots were quantified as described (33 systems, Inc.) as described (35) . After the addition of 100 A1 ofmineral oil, the reactions were heated to 950C for 5 min and immediately cycled 30 times in a programmable heating block (Coy Laboratory Products Inc., Ann Arbor, MI) through 30 cycles consisting of 1 min of denaturation at 940C, 5 min of annealing and extension at 65°C, and 20 min of extension at 65°C. In most cases, 10-15 ul of the PCR reaction product were directly separated through a 0.5% Nusieve agarose/0.5% agarose mixture (wt/vol) and visualized by staining with ethidium bromide. Sizes ofthe PCR products were estimated from the migration ofDNA size markers ( 123-bp ladder) run concurrently. The PCR products were transferred from gels to Nytran membranes by capillary blotting (35) . Southern-blotted membranes were probed with a 32P-labeled hybridization oligonucleotide targeted to a region internal to the PCR reaction product (Table I) . Control PCR reactions included water blanks as well as samples in which reverse transcriptase was omitted.
The CYP3A7 primers were chosen to provide maximum discrimination between CYP3A7 and the other human CYP3A gene family members. The primers were: antisense CYP3A7 primer, bases 1,723-1,743 ofthe CYP3A7 sequence (24) ; sense primer, bases 1,189-1,212; internal oligonucleotide primer, bases 1,586-1,611. It should be noted that the last exon ofCYP3A7 begins at bp 1,480, which would, because ofthe intervening intron, allow easy discrimination between the amplified cDNA and genomic DNA (unpublished observation, Schuetz, J. D.). The mismatches of these primers with the other human CYP3A family members are shown in Table II. PCR subcloning and DNA sequence determination. The ends ofthe PCR products were repaired by adding the Klenow fragment (5 Kunitz U) ofPolI to the PCR reaction after a 10-min incubation at 95°C. The enzymatically repaired PCR products were then phenol extracted, precipitated with ethanol, and subcloned in both orientations into SmaI site ofM 13 (37). Single-stranded M 13 was prepared from plaque-purified recombinants to determine the nucleotide sequence of the cloned insert using the method of Sanger et al. (38) (Fig. 1) . By comparing the migration patterns for endometrial or placental microsomes with that for a sample of human liver microsomes known to contain CYP3A3/4 plus CYP3A5 (HL 34) but not CYP3A7, we found that the CYP3A immunoreactive band associated with endometrium or placenta migrated between the CYP3A3/4 and CYP3A5 immunoreactive bands (Fig. 1) . Finally, the rate ofmigration ofthe CYP3A immunoreactive band in endometrial and placental microsomes was identical with that in a sample ofhuman fetal liver microsomes known to contain only CYP3A7 (Fig. 1) .
Quantification of CYP3A immunoreactivity in gestational human endometrium and placenta. Immunoreactive protein was detectable in each of the five endometrial and four placental microsomal samples available for analysis (Table I) . We carried out a quantitative analysis of our immunoblots, taking the assumption that our polyclonal human anti-CYP3A antibody has equal affinity for the proteins it identifies in placenta, endometrium, and liver. Calculated in this way ( (Table I) . However, because fetal liver is < 20% of the placental weight during the second trimester, the endometrium and placenta are a quantitatively important site of CYP3A7 expression. PCR analysis of CYP3A mRNA in human endometrium and placenta. Next, we analyzed RNA from endometrium and placenta for the presence of CYP3A mRNA and, on the basis of the results of the immunoblot analysis, we focused on CYP3A7 mRNA, specifically. Recognizing that CYP3A7 mRNA species would not likely be abundant in these tissues, we prepared cDNA copies of the mRNAs in endometrial and placenta RNA specimens and then combined these cDNAs with CYP3A7-specific oligonucleotides (see Fig. 2 legend and Table II ) to amplify any CYP3A7 cDNA that might be present by the sensitive PCR technique (see Methods). We found for both endometrium and placenta that PCR produced a consistent product that was the exact size of the predicted target sequence (Fig. 2) . Moreover, the amplified product hybridized with a unique oligonucleotide constructed to bind to a region within the expected amplified CYP3A7 sequence (see Methods). Finally, the DNA sequence ofthe PCR-synthesized product (Fig. 2) proved to be identical to the published CYP3A7 sequence (24) .
Expression ofCYP3A 7 mRNA in human endometrium. To determine the pattern of maternal expression of CYP3A7 mRNA, we analyzed RNA isolated from gestational and nongestational endometrium (Fig. 3 A) women during the proliferative phase of the menstrual cycle (Fig. 3 A, sample B) , we found that only one of six contained hybridizable CYP3A7 mRNA and even this signal was, at best, weakly positive. In contrast, among RNA samples taken during the secretory phase ofthe menstrual cycle, the frequency of detectable CYP3A7 mRNA was higher (three out of six were positive). The average amount ofhybridizing CYP3A7 mRNA in these three was sixfold higher than the value for the single positive sample from the proliferative phase (see Fig. 3 A) . We also found that CYP3A7 mRNA was more frequently detected in endometrial RNA samples from pregnant (Fig. 3 A, gestational, 6 of 7) compared with nonpregnant women (Fig. 3  A, proliferative and secretory, 4 of 12) and that the amount of hybridizable endometrial CYP3A7 RNA was higher in the samples from pregnant compared with the positive samples from nonpregnant women (average increase was 12-fold, [P < 0.05 ]). A similar RNA analysis carried out on a second set of seven endometrial samples obtained from pregnant patients revealed that five of these were positive for CYP3A7 mRNA (not shown).
Compared with human fetal liver, the amount of endometrial CYP3A7 hybridizable mRNA in pregnancy during the second trimester was -10%, although in one of our samples (Fig. 3 A, 1 6-wk gestational endometrium) the amount of hybridizable CYP3A7 mRNA was similar. The increased amounts ofCYP3A7 mRNA associated with gestation appears to be specific because rehybridization ofthis blot with a fl-actin cDNA probe gave signals ofequal intensity among these endometrial samples (data not shown). Moreover, the endometrium did not appear to be contaminated by placenta because endometrial RNA showed no hybridization with a placental lactogen cDNA probe (data not shown) (34) . Unfortunately, there were no microsomal samples available from this set of patients analyzed for endometrial CYP3A7 mRNA.
Expression of CYP3A7 mRNA in human placenta. The time course of expression of CYP3A7 mRNA in the placenta was examined by extracting total RNA from 16 placental samples isolated at various times of gestation and analyzing these on Northern blots hybridized with the CYP3A7 cDNA. There was little expression ofCYP3A7 mRNA in the first 12 wk (one of eight samples gave a minimal hybridization signal, the others were negative, see Fig. 3 B) . However, immunoreactive CYP3A protein was present in both of the patients (both were CYP3A7 mRNA negative) for whom microsomal samples were available (C.S., the 8-wk sample, and M.H., the first 12-wk sample from left to right, Table I ). Second trimester samples were more frequently positive for CYP3A7 mRNA (four of eight samples, Fig. 3 B) and the amounts of CYP3A7 mRNA were greatly increased (the average of these four was about sevenfold higher than the single positive of the first trimester samples). We noted that the apparent size ofthe hybridizing mRNA species in placenta was the same as that in endometrium and in fetal liver (2.1 kb), although, in one placental specimen a second hybridizing mRNA ('-2.7-kb) species was detected (see 12.5 wk, Fig. 3 B) . This larger form of hybridizable CYP3A7 mRNA may represent use of an alternate polyadenylation signal as has been described for CYP3A4 (43) .
Discussion
These experiments demonstrate that human endometrium and placenta contain CYP3A7, an enzyme that previously was thought to be expressed only in human fetal liver (24, 25, 44) .
Immunochemical techniques demonstrated the appropriate size and immunoreactivity of the CYP3A7 protein accompanied by the appearance of CYP3A7 mRNA documented by PCR, DNA sequence analysis, and Northern blot analysis. Finally, because we have detected a single immunoreactive band with the anti-CYP3A antibody, our immunoblots suggest that CYP3A7 is the predominant, if not only, CYP3A expressed in the endometrium and placenta. This conclusion is supported by our failure to detect by PCR mRNAs specific for the other CYP3A members (CYP3A4 [40] , and CYP3A5 [35] , unpublished observations). The greater frequency of detection of CYP3A immunoreactive protein compared with CYP3A7 mRNA could be due to differences in stability of these gene products, although more opportunities to examine both microsomes and RNA from the same patient are needed to investigate this question.
Finding CYP3A7 protein and CYP3A7 mRNA in human endometrium and placenta strengthens the concept that these tissues are important sites for intermediary steroid metabolism. Although we did not measure the metabolic capability of the placental microsomes, the functional activity of placental CYP3A7 can be reasonably inferred from previous studies of placental microsomes or placental explants that document biotransformation reactions (45, 46) associated with CYP3A, including formation of 6-f3 hydroxycortisol from cortisol (7, 9) and production of estriol (a product of 16-a-hydroxylation of DHEA-s) ( 12) . These activities suggest that despite the low concentration of CYP3A7 in the endometrium and placenta relative to that in fetal liver, the large amounts ofthese extrahepatic tissues makes this enzymatic activity important to intermediary steroid metabolism during pregnancy.
We (47) and others (33) have shown that P450s of the CYP3A family in the liver are inducible. For example, the amount of hepatic CYP3A immunoreactive protein and CYP3A mRNA increases in response to administration ofsynthetic and natural glucocorticoids (33, 47) , macrolide antibiotics (48), some antiseizure and antifungal drugs (49) , and such environmental agents as polychlorinated biphenyls (PCBs) and organochlorine pesticides (50) . We observed an increase in the amounts of CYP3A7 protein and CYP3A7 mRNA in endometrium/placenta associated with increasing gestational age (Table I and Fig. 3, A and B) . We cannot rule out the possibility that the increase could be related in some manner to the source of these tissues (surgical patients) or could be due to enzyme induction by fetal exposure to PCBs, dichlorodiphenyltrichloroethane, and other persistent lipophilic environmental agents that are virtually ubiquitous in the general United States population ( 51 ). However, the increase in CYP3A7 immunoreactive protein and mRNA occurred consistently in the second trimester in both placenta and endometrium from different individuals (Table I and Fig. 3, A and  B) . Furthermore, human CYPlA1 (52), and epoxide hydrolase (53) , enzymes that are induced by xenobiotics in the liver, are expressed constitutively in the placenta. We believe a better explanation is that changes in the amounts ofendogenous substrates and hormones that can affect CYP3A expression in the liver (54) also underlie the developmental regulation of CYP3A7 in the placenta.
Transcription of CYP3A 1 is controlled by a nonclassical glucocorticoid receptor-mediated process (47, 55) . Moreover, the synthetic glucocorticoid agonist, dexamethasone, induces CYP3A7 mRNA in the human hepatoblastoma HEPG2 (56, 57) through transcriptional activation of CYP3A7 (unpub-lished observations). These observations suggest that steroid hormones and their receptors play a role in the regulation of CYP3A7. The time course of increase in endometrial and placenta CYP3A7 protein and mRNA during pregnancy coincides with an increase in systemic levels of DHEA-s (12), a known substrate for CYP3A7 (21, 23) . Substrate mediated induction of CYP3A7 through DHEA-s bound to its receptor (58) could account for the increased placental and endometrial CYP3A7 mRNA and protein we have found during pregnancy. Another possibility is that circulating glucocorticoids regulate placental/endometrial CYP3A7 just as they do in the liver. Even though systemic glucocorticoid levels do not appreciably change during the intervals of pregnancy we examined ( 12) , the amount ofplacental glucocorticoid receptor increases from 7-to 12-fold from first to second trimester, a value that, coincidentally, corresponds with the large increase in CYP3A7 mRNA and protein expressed in the placenta (Fig. 3 B and Table I ). Because the amount ofglucocorticoid receptor can be rate limiting for transcriptional activation of a gene by a glucocorticoid (59) , it is possible that despite adequate systemic steroids CYP3A7 is not transcribed until the amount ofglucocorticoid receptor increases. It is intriguing that administration of dexamethasone to pregnant women near term can increase the metabolism of DHEA-s to estriol (60), a conversion that could be controlled by CYP3A7.
We have considered why CYP3A7 is expressed and developmentally regulated in the placenta and endometrium. CYP3A7 was previously thought to be expressed only in fetal liver during early pregnancy (24, 25) , perhaps to protect the fetus from DHEA-s toxicity (23) . When fetal adrenals are stimulated by ACTH in the second trimester, synthesis of DHEA-s increases. Accumulation of excess DHEA-s is associated with intrauterine growth retardation (61 ) , possibly because of inhibition of cell proliferation and differentiation by DHEA-s (62) . If the rise in DHEA-s stimulates extrahepatic expression of CYP3A7 in the second trimester, this enzyme could provide additional protection for the fetus by forming the nontoxic 1 6-a-hydroxylated DHEA-s metabolite. Another possible adverse effect of DHEA-s is suppression of the synthesis of progesterone, a hormone critical for maintaining pregnancy ( 12) . An increase in placental CYP3A7 could divert the substrate flow to 16-ahydroxylated DHEA-s, a steroid that has no affect on progesterone synthesis ( 17) . Finally, an important but as yet unexplored possibility is that, because some CYP3A forms can both activate and inactivate carcinogens (63) (64) (65) (66) (67) , the change in the amount of CYP3A7 expressed in the reproductive system throughout pregnancy (if this enzyme carries out similar reactions) may play an important role in fetal toxicology during the critical periods in fetal development.
